Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 22, 2023

Details for Patent: 9,480,682

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,480,682 protect, and when does it expire?

Patent 9,480,682 protects GALAFOLD and is included in one NDA.

This patent has thirty-nine patent family members in seventeen countries.

Summary for Patent: 9,480,682

Title:	Methods for treatment of Fabry disease
Abstract:	Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
Inventor(s):	Lockhart; David (Del Mar, CA), Castelli; Jeff (New Hope, PA)
Assignee:	Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:	14/641,707
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,480,682
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 9,480,682

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				THE TREATMENT OF FABRY PATIENTS	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,480,682

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007253900	See Plans and Pricing
Canada	2652553	See Plans and Pricing
Cyprus	1115180	See Plans and Pricing
Cyprus	1117656	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt

Harvard Business School

AstraZeneca

Johnson and Johnson

Dow

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.